Crucially, pharmacological inhibition of NOS1 with Nω-propyl-L-arginine selectively curbed tumor growth in hypercholesterolemic models, suggesting a therapeutic strategy with reduced off-target toxicity. Here, NOS1 is linked to neoplasm.